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Abstract
Patients with HIV infection have decreased numbers of osteoblasts, decreased bone mineral density and increased risk of
fracture compared to uninfected patients; however, the molecular mechanisms behind these associations remain unclear.
We questioned whether Gp120, a component of the envelope protein of HIV capable of inducing apoptosis in many cell
types, is able to induce cell death in bone-forming osteoblasts. We show that treatment of immortalized osteoblast-like cells
and primary human osteoblasts with exogenous Gp120 in vitro at physiologic concentrations does not result in apoptosis.
Instead, in the osteoblast-like U2OS cell line, cells expressing CXCR4, a receptor for Gp120, had increased proliferation when
treated with Gp120 compared to control (P,0.05), which was inhibited by pretreatment with a CXCR4 inhibitor and a G-
protein inhibitor. This suggests that Gp120 is not an inducer of apoptosis in human osteoblasts and likely does not directly
contribute to osteoporosis in infected patients by this mechanism.
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Introduction
Prior to the advent of highly active antiretroviral therapy
(HAART), HIV infection was considered to be ultimately fatal.
However, administration of HAART, particularly in resource-rich
settings, has dramatically changed the clinical course of the
disease, with patients newly infected with HIV now expected to
have a near normal life expectancy. With this increased life
expectancy, though, has come the recognition of many long term
consequences of chronic HIV infection, including insulin resis-
tance and the metabolic syndrome, accelerated cardiovascular
disease, and increased risk of malignancy, that are typically
associated with aging [1]. HIV-infected patients also have lower
bone mineral density, and higher prevalences of both osteopenia
and osteoporosis, compared to age and sex matched HIV-
uninfected controls [2–4]. This translates into an increased risk
of fracture and decreased rate of fracture healing [5,6]. The cause
of the increased bone disease seen in HIV infection, however,
remains unclear.
Osteopenia and osteoporosis generally result from an uncou-
pling of the homeostatic balance between bone resorbing
osteoclasts and bone forming osteoblasts [7]. Several mechanisms
have been proposed to account for the increased bone disease seen
in HIV infected patients. Traditional risk factors for osteoporosis,
including low body mass index, inactivity, and tobacco and
alcohol use, are over-represented in the HIV-infected population.
Other contributing factors seen in chronically HIV-infected
patients include Vitamin D deficiency, hypogonadism, and hyper-
parathyroidism secondary to chronic renal insufficiency [3,4].
Antiretroviral therapy itself, and particular medications such as
tenofovir and protease inhibitors, may contribute to bone disease,
either indirectly through renal phosphorous wasting and hyper-
parathyroidism in the case of tenofovir, or directly through
stimulation of osteoclastogenesis by protease inhibitors [8–10].
The chronic immune activation and elevated levels of pro-
inflammatory cytokines seen in HIV infection, particular tumor
necrosis factor a (TNFa), interleukin 6 (IL-6) and RANKL,
may stimulate osteoclastogenesis and osteoclast activity [11,12].
However, there have been few studies investigating the direct
effect of HIV-infection on bone forming osteoblasts. Histomor-
phometric examination of bone biopsy samples from HIV-infected
patients reveal decreased number and activity of osteoblasts
compared to uninfected controls [13]. However, human osteo-
blasts are unable to be infected with the HIV virus, likely due to
low level expression of the cell surface receptor CD4 required for
cell attachment and entry [14–15].
Several investigators have questioned whether HIV-associated
proteins have direct effects on osteoblast number or function.
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transmembrane Gp41) of the Gp160 HIV envelope protein, and is
expressed on the surface of infective HIV virions and HIV-infected
cells. Gp120 on virions binds to the CD4 cell surface receptor, and
when engaged with one of two cellular co-receptors (CCR5 or
CXCR4), leads to membrane fusion of the virus and host cell and
consequent cell entry. Later in the life cycle of the virus, Gp120
is expressed on the cellular membrane and is incorporated into
the membrane of the budding virus. Gp120 can be detected in
the serum and extracellular tissue matrices of HIV-infected
patients, even in the presence of suppressive antiretroviral therapy
[16]. Therefore, Gp120 would make a logical candidate for a
protein-induced pathologic effect on osteoblasts in HIV infection.
Exogenous treatment of osteoblasts with the HIV envelope glyco-
protein Gp120 or p55-gag protein decreases osteoblast function, as
measured by calcium deposition and alkaline phosphatase
expression, through a decrease in RUNX2 and an increase in
PPARc expression [17]. Furthermore, Gp120 induces apoptosis in
a number of cell types, including CD4 T lymphocytes, neurons,
hepatocytes, and cardiomyocytes [18]. Gibellini et al demonstrat-
ed that inactivated HIV virus and recombinant Gp120 were able
to induce apoptosis in primary human osteoblasts and an
immortalized osteoblast-like cell line (HOBIT) in vitro through a
mechanism that is partially inhibited by blocking antibodies to
TNFa [19].
In this investigation, we sought to confirm a cytotoxic effect of
Gp120 on osteoblasts in vitro, and to determine which cellular
receptor(s) (CD4, CCR5 or CXCR4) and signaling mechanism(s)
are necessary for Gp120-induced apoptosis of osteoblasts. This
information could have direct implications on developing thera-
pies to prevent or reverse the accelerated bone disease seen in
HIV-infected patients. On the contrary, our results suggest that
Gp120 is not directly cytotoxic to human osteoblast-like cells,
and may actually induce proliferation in a small proportion of
osteoblast-like osteosarcoma cells through engagement with
CXCR4.
Methods
Cell Lines and Culture
Jurkat T cells (American Type Culture Collection, Manassas,
VA) were maintained in RPMI medium (Mediatech, Inc,
Manassas, VA) supplemented with 10% heat-inactivated fetal calf
serum (FCS) and 2 mM L-glutamine, and passed twice weekly.
Human osteoblast-like cell lines, including fetal osteoblasts (FOB)
[20], human osteoblast-like SV-40T antigen immortalized cell line
(HOBIT) [21], and the U2OS osteosarcoma cell line [22], were
maintained in DMEM/F12 medium (Gibco, Carlsbad, CA)
supplemented with 10% heat-inactivated fetal calf serum and L-
glutamine. Primary human osteoblast cultures from two HIV-
uninfected donors (HOB-1 and HOB-2) were obtained from
Promocell (Heidelberg, Germany) and maintained in the Promo-
cell Osteoblast culture medium. Osteoblast cultures were passed
when the culture reached 80–90% confluence, and were harvested
by trypsin for the immortalized cell lines, and with the Promocell
Detach Kit for the primary osteoblasts per the manufacturer’s
protocol. All cultures were maintained at 37uC in a humidified
atmosphere containing 5% CO2. Prior to experiments, osteoblast
cultures were harvested, washed in complete medium, replated in
medium containing 2% FCS, and treated as described. Reagents
were obtained from the following companies: Recombinant HIV-
1IIIb Gp120 (ImmunoDiagnostics, Inc.); Etoposide (Sigma); Insulin
(Sigma); TNFa (R&D Systems); skTRAIL (Axxon Life Sciences);
AMD3100 (NIH AIDS Research and Reference Program);
Pertussis Toxin (CalBiochem); agonistic monoclonal antibody to
Fas -CH11- (Millipore); PE labeled anti-human CD4, PE labeled
anti-human CXCR4, and PE labeled anti-human CCR5 (BD
Pharmingen).
Cell Viability and Death Assays
Cell viability was measured by exclusion of trypan blue and
propidium iodide staining by light microscopy and flow cytometry
respectively. Treatment with etoposide (10 mM) was used through-
out as a positive control. Briefly, cells treated as described was
harvested with trypsin, washed and resuspended in PBS. In the
case of trypan blue staining, an aliquot was stained with an equal
volume of trypan blue, and live and dead cells counted on a
hemocytometer under light microscopy. Percent Viability was
calculated as the number of live cells (trypan blue negative) divided
by the total number of cells multiplied by 100. For PI staining, cells
were resuspended in 1 ml PBS. PI (Sigma) was added to a final
concentration of 1mg/ml, and cells were incubated for 30 minutes
in the dark prior to flow cytometry analysis on unfixed samples. All
flow cytometry was performed on a FACScan (Becton Dickinson)
flow cytometer and analyzed with FlowJo software (Version 5.7.2,
Tree Star, Inc.).
Hypodiploid DNA, a marker of apoptosis, was assessed as
follows. Treated cells were harvested with trypsin, washed, and
fixed in 70% ethanol and incubated at 220uC until staining. Cells
were thawed, washed in PBS, and resuspended in 1 ml of staining
buffer containing 20mg/ml propidium iodide, 0.2 mg/ml DNase-
free RNase A (Sigma) and 0.1% (v/v) Triton-X in PBS. Cells were
incubated at room temperature in the dark and analyzed by flow
cytometry.
Active caspase 3 expression was assessed as follows. Treated
cells were harvested, washed and permeabilized in PBS containing
0.2% Tween20 (Sigma) at 37uC for 15 minutes, washed in PBS
with 5% FCS, and stained with PE labeled rabbit anti-human
active caspase 3 or isotype antibody (BD Pharmingen) at 4uC for
1 hr. Cells were then washed and fixed in 2% paraformaldehyde
and analyzed by flow cytometry.
Cell Proliferation Assays
Cellular proliferation was assayed by measurement of ATP
production using the Cell-Titer Glo Luminescent Assay (Pro-
mega). Osteoblasts were harvested as above, plated in 96 well
microtiter plates at a density of 5610
5 cells/well, and allowed to
adhere overnight. The following day, the cells were treated as
described in 200ml medium in triplicate. At the appointed time,
the medium was aspirated, and 50ml Cell-Titer Glo Reagent was
added to each well, and incubated in the dark at room
temperature for 15 minutes. Luminescence was measured on
10 ml aliquots on a Lumat LB 9501 luminometer. Percent change
in ATP content was calculated for each time point as the relative
light units emitted per well divided by the mean of the control
sample triplicate multiplied by 100.
Cellular proliferation determination by CFSE dilution was
measured using the CellTrace CFSE Cell Proliferation Kit
(Molecular Probes) according to the manufacturer’s protocol. In
brief, cells were harvested with trypsin, washed in PBS, and
resuspended in PBS with 0.1% BSA at a concentration of 1610
6
cells/ml. 1ml of a 5 mM stock CFSE solution in DMSO was added
and vortexed. Cells were incubated with dye at 37uC in the dark
for 10 minutes, and then staining quenched by addition of 5
volumes ice-cold complete media and incubated on ice for 5
minutes. Cells were washed three times in complete media and
then cultured in 12 well plates overnight at 37uC prior to
treatment as described. At the appointed time, cells were again
HIV-1 Gp120 and Osteoblast Proliferation
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24876harvested with trypsin, washed, co-stained with a PE labeled anti-
CXCR4 or isotype antibody as appropriate, washed, and fixed
with 2% paraformaldehyde for flow analysis. CFSE dilution was
calculated using the division index analysis function in the FlowJo
Software.
Intracellular Ki-67 expression was measured via flow cytometry
per manufacturer’s protocol using FITC-labeled, mouse anti-
human Ki-67 (BD Pharmingen). Briefly, cells were treated as
described and harvested with trypsin, washed in PBS, and fixed in
cold 70% ethanol while vortexing. Fixed cells were incubated at
220uC until staining. For staining, fixed cells were thawed to
room temperature, washed in PBS with 1% FCS, and resuspended
in 100ml PBS with 1% FCS in a 6 ml FACS tube. 20ml FITC
labeled anti-Ki-67 antibody or isotype control was added and cells
incubated at room temperature in the dark for 20 minutes. Cells
were again washed in PBS and fixed in PBS with 2%
paraformaldehyde for flow analysis.
Statistical Analyses
Values are expressed as mean values +/2 standard error,
except when indicated otherwise. Comparisons were made using
the student’s t-test. A P value of ,0.05 was considered statistically
significant.
Results
Recombinat Gp120 does not induce cell death in
osteoblast-like cell lines
Because the number of osteoblasts is decreased in HIV-infected
patients, and Gp120 has been shown to have pro-apoptotic effects
on multiple cell types, we first sought to determine whether Gp120
induces apoptosis in human immortalized fetal osteoblasts (FOB
cells) and human osteoblast-like osteosarcoma cells (U2OS cells)
that were cultured in the presence or absence of recombinant HIV
strain IIIB derived Gp120 over several days. We independently
confirmed the biologic activity of the recombinant Gp120 by
demonstrating that pre-treatment of Jurkat T cells with Gp120
(1 mg/ml) for 48 hours increased susceptibility to apoptosis
induced by T-cell receptor ligation compared to BSA pre-
treatment (Supplementary Figure S1). Because Gp120 can be
both pro- or anti-apoptotic in similar models at varying con-
centrations, FOB cells were treated with Gp120 over a wide dose
range (100 pg/ml to 5 mg/ml), which did not alter cell viability
within 96 hours after treatment (Figure 1A and 1B). Furthermore,
Gp120 treatment did not induce DNA hypodiploidy within
48 hours, or the expression of active Caspase 3 within 6 days in
FOB cells (Figure 1C and 1D). Similar results were seen with
U2OS osteosarcoma cells, and primary human osteoblasts from
two HIV-uninfected donors (data not shown). These results
indicate that Gp120 itself does not induce apoptotic cell death in
these osteoblasts tested.
Because Gp120 has been shown to increase T cell susceptibility
to death-ligand induced apoptosis [23,24], we questioned whether
Gp120 treatment would increase osteoblast susceptibility to cell
death induced by TNFa, skTRAIL or an agonistic monoclonal
antibody to Fas (CH11). However, Gp120 treatment, when
compared to untreated controls, did not increase osteoblast cell
death in response to TNFa (10 ng/ml), skTRAIL (100 ng/ml) or
CH11 (500 ng/ml) (Supplementary Figure S1C) as measured by
trypan blue exclusion and ATP content.
We next questioned whether, instead of directly or indirectly
inducing cell death, Gp120 inhibited proliferation of osteoblasts.
FOB and U2OS cells were cultured in the presence or absence of
Gp120, and cellular proliferation determined by measurement of
Figure 1. Gp120 does not induce cell death in osteoblasts. FOB cells were cultured in the presence or absence of Gp120 (2mg/ml) in low
serum media and assessed for viability by trypan blue exclusion (A), and propidium iodide staining (B). Apoptosis, as indicated by hypodiploid DNA
(C) and active caspase 3 expression (D), was assessed by flow cytometry. Etoposide (10mM) was used as a positive control. Results are representative
of $3 independent experiments.
doi:10.1371/journal.pone.0024876.g001
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treatment of osteoblasts did not significantly decrease ATP content
(Figure 2A), CFSE dilution (Figure 2B), nor Ki67 expression
(Figure 2C), when compared to controls, indicating that Gp120
treatment did not inhibit proliferation of the osteoblast cell lines
tested.
Osteoblast-like cells express the CXCR4 co-receptor, and
Gp120 treatment results in proliferation of CXCR4+
osteosarcoma cells
Gp120 binds to one or more of several cell surface receptors,
including CD4, CCR5 or CXCR4. Human osteoblasts have been
shown to express varying levels of all three of these surface
receptors [15,19]. We questioned whether the lack of apoptosis
induced by Gp120 in osteoblasts was associated with a lack
of surface expression of the cellular receptors. Varying degrees
of CXCR4 protein expression on the cell surface were seen in
the FOB, HOBIT and U2OS osteoblast cell lines, as well as
in two primary osteoblast cell lines (HOB-1 and HOB-2). On
the other hand, very minimal CD4 or CCR5 expression was
observed, as evidenced by neither a significant shift in the
mean channel fluorescence nor a significant identifiably positive
staining population for that particular cell type and receptor
(Figure 3A).
Because only a small proportion of the osteoblast-like cells
expressed a receptor for Gp120 to bind, subtle effects of Gp120
treatment on this subpopulation could be easily missed when
accounting for the total population. Therefore, we questioned
whether Gp120 treatment may selectively induce apoptosis or
inhibit proliferation in osteoblasts expressing CXCR4. By co-
staining with a monoclonal antibody to CXCR4, Gp120 did not
induce active Caspase 3 expression in CXCR4+ osteoblasts within
6 days after treatment (Supplementary Figure S1D). However,
Gp120 treatment did increase CFSE dilution by nearly two-fold by
48 hours in CXCR4+ U2OS cells when compared to untreated
cells (P,0.05, Figure 3B). In order to assess the specificity of the
Gp120 interaction with CXCR4 (a G-protein coupled receptor
[25]), U2OS cells were pretreated with either the CXCR4
antagonist AMD3100 [26] or the G-protein inhibitor pertussis
toxin [27]. Pretreatment with both AMD3100 and pertussis toxin
abrogated this proliferative effect in CXCR4+ cells, (Figure 3C).
These results suggest that Gp120 induces proliferation specifically
in CXCR4+ osteoblast-like U2OS cells. Similar results were not
seen in the other osteoblast cell lines tested.
Discussion
In this study, we demonstrate that the HIV envelope protein
Gp120, contrary to a single previous report, does not induce cell
death in a variety of human osteoblast-like cell lines. Our data also
suggest that in a small proportion of osteoblast-like U2OS cells
that express CXCR4, Gp120 may actually have a proliferative
effect that is G-protein dependent. The pathophysiologic impor-
tance of this latter finding in transformed cells is unclear.
There are several potential reasons why our results did not
replicate earlier published reports. First, Gibellini et al tested for
Gp120 receptor expression on HOBIT cells and primary
osteoblasts [19]. They demonstrated minimal (,5%) surface
positivity for CD4 and CXCR4, and nearly 15% positivity to
CCR5 by flow cytometry, whereas we detected minimal CD4 and
CCR5 expression, with widely varying degrees of CXCR4
expression, albeit in different cell lines. Because pre-treatment of
the HIV and Gp120 with soluble CD4 abrogated the apoptosis,
the authors argued for a CD4 dependent mechanism, despite data
from their study and others that demonstrate minimal CD4
expression on osteoblasts [15]. Therefore, it is possible that
differences in study findings could be attributable to differences in
cell surface expression in cell lines tested. Second, the physiologic
level of Gp120 that is actually present in either plasma or tissues in
HIV-infected patients remains controversial, and has varied in in
vitro studies from pM to mM ranges [28,29]. We tested a wide
Figure 2. Gp120 does not inhibit osteoblast proliferation. A. FOB and U2OS cells were cultured in the presence or absence of Gp120 (2mg/ml)
in low serum media and assessed for proliferation by measuring ATP content as described in Methods. Mean (SEM) values of sample triplicates
relative to control are depicted for FOB cells. B. Proliferation in FOB and U2OS cells at 48 hrs was measured by flow cytometry by CFSE dilution (B) and
expression of intracellular Ki-67 (C). Mean (SEM) values of 3 independent experiments with U2OS cells are represented.
doi:10.1371/journal.pone.0024876.g002
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T-tropic IIIB strain used in previous studies, with no apoptosis-
induction seen. Third, in the prior study, only analysis of hy-
podiploid DNA content was assessed, whereas we assessed cell
death and apoptosis by several flow cytometry and non-flow based
techniques. Finally, the earlier study contrasts with our data, since
the Gp120-induced apoptosis was partially inhibited by treatment
with anti-TNF neutralizing antibodies. However, our data suggest
that osteoblast like cells are actually resistant to TNFa-induced
apoptosis (data not shown), and are consistent with other reports
that osteoblasts are relatively resistant to induction of apoptosis by
TNF-superfamily ligands, possibly due to expression of non-signal
transducing decoy receptors [30] [31,32].
Gp120 has been shown to induce proliferation in multiple cell
types other than osteoblasts in vitro. Gp120 induces B cell
proliferation and immunoglobulin production [33], and X4 tropic
Gp120 increases Epstein Barr Virus-induced transformation in
normal B cells [34]. These effects may contribute to both the
polyclonal B cell activation and increased frequency of Non-
Hodgkin Lymphoma seen in HIV infected patients. Gp120
treatment of vascular smooth muscle cells results in increased
proliferation compared to control, possibly through an octapeptide
of Gp120 that has sequence homology with neuropeptide Y
and signals through the NPY receptor [35]. This effect may
contribute to the increased vascular smooth muscle cell hyperpla-
sia and accelerated cardiovascular and microvascular disease seen
in clinical HIV infection. Interestingly, Gp120 has bimodal,
concentration dependent effects on multiple types of kidney cells,
possibly contributing to HIV-associated nephropathy and focal
segmental glomerulosclerosis. At lower concentrations, Gp120
induces proliferation of kidney fibroblasts, glomerular epithelial
cells, and mesangial cells, whereas at higher doses it induces
apoptosis [36,37] [38]. Postulated signaling mechanisms for the
proliferative effects of Gp120 include upregulation of pro-survival
transcription factors, including c-fos and c-jun, activation of
protein kinase C and tyrosine kinase pathways, and activation of
Akt and/or NFkB.
While our data suggest that Gp120 does not have a direct
cytotoxic effect on osteoblasts in vitro, it is still possible that Gp120
effects bone metabolism in vivo through other mechanisms. It may
partially counteract the many pro-osteoporosis mechanisms seen
in HIV infection, thereby decreasing the observed overall rate of
bone loss. Alternatively, Gp120-induced osteoblast proliferation in
the short term may contribute to replicative senescence, and
exhaustion of the total osteoblast pool, a process which has been
implicated in normal age-related bone loss [39]. This is akin to the
immune exhaustion of virus-specific CD8 T cells, which, due to
persistent antigenic stimulation and chronic immune activation in
HIV infection, become anergic and lose proliferative capacity
[40]. On the other hand, in one study treatment of primary
human osteoblasts in vitro with recombinant Gp120 at a dose of
100 ng/mL decreased RUNX2 expression, alkaline phosphatase
activity and calcium deposition, as well as increased PPARc and
lipid staining, suggesting that Gp120 may inhibit osteoblast
function and promote adipogenesis; similar effects were not seen
in mesenchymal stem cells treated with Gp120 in that study.[17].
However, the same group more recently reported that Gp120
treatment of mesenchymal stem cells increases adipogenesis under
adipogenic media conditions, and decreases alkaline phosphatase
activity in normal media [41]. If Gp120 does indeed upregulate
TNFa production by osteoblasts, this could promote osteoclast
generation and activity [42]. Gp120-exposed T cells in vitro
produce RANKL which also stimulates osteoclast generation and
activity [10]. Any potential effects that Gp120 might have on
osteoblast chemotaxis by competing with the natural ligands for
CXCR4 and/or CCR5 would be import to study.
Figure 3. Gp120 induces proliferation in CXCR4 positive U2OS cells. A. Surface expression of CD4, CCR5 and CXCR4 was assessed by flow
cytometry in the osteoblast cell lines noted. Jurkat T cells were used as a positive staining control. The darker line represents the isotype antibody
control. B. Relative proliferation in CXCR4 positive (CXCR4+) and CXCR4 negative (CXCR4-) U2OS cells was measured by CFSE dilution at 48 hrs. Mean
(SEM) division index values of 3 independent experiments relative to untreated controls are represented. * indicates P,0.05. C. U2OS cells pretreated
with AMD3100 (5mM) or Pertussis toxin (1mg/mL) for 30 minutes prior to exposure to Gp120 (2 mg/ml), and CFSE dilution was measured at 48 hrs.
Representative results from one experiment of three are presented.
doi:10.1371/journal.pone.0024876.g003
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Figure S1 A. Jurkat T cells were pretreated with either Gp120
or BSA (1 mg/mL) for 48 hours, and then apoptosis was induced
by sequential treatment with 2 mg/ml phytohemagglutinin (PHA)
on day 3, 50 U/ml interleukin 2 (IL-2) on day 4, and then 35 mg/
ml OKT-3 on day 5. Depicted is mean (SEM) viability by trypan
blue exclusion of 3 independent experiments. B. Primary human
osteoblasts (HOB-2) were treated with Gp120 (2 mg/ml) or
etoposide (positive control), and cell viability measured by trypan
blue exclusion. Results are representative of $2 independent
experiments in two primary human osteoblast cell lines. C. U2OS
cells were treated with TNFa (10 ng/mL) alone or with Gp120
(2 mg/ml) and cell viability measured over time by ATP content
(see Methods). Depicted results are representative for similar
results obtained with skTRAIL and anti-Fas treatment in both
U2OS and FOB cells. D. U2OS cells were treated with Gp120 or
control, and active caspase 3 expression assessed by flow cytometry
in cells expressing CXCR4 and those not expressing CXCR4.
(TIF)
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